Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Hemangioendothelioma, Epithelioid × eribulin × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 9 Triple Negative Breast Neoplasms 5 Neoplasm Metastasis 3 Urinary Bladder Neoplasms 2 Inflammatory Breast Neoplasms 2 Carcinoma, Transitional Cell 2 Urethral Neoplasms 1 Ureteral Neoplasms 1 Sarcoma 1 Liposarcoma 1 Hemangiosarcoma 1 Hemangioendothelioma, Epithelioid 1 HR+HER2- Breast Cancer 1 Colorectal Neoplasms 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03331250 2025-12-23

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

Massachusetts General Hospital

Phase 2 Active not recruiting

13 enrolled 9 charts

Hemangiosarcoma, Hemangioendothelioma, Epithelioid

Data powered by HemOnc (CC BY 4.0) Colophon ⚡